

Practice:	Mr	ROSEE	Paul	03/09/1943	Male
Lab:	893560721-C-C924	ROSEE	PAUL	03/09/1943	Male
Provider:	Douglass Hanly Moir Pathology				

Medicare: 2151 88807 9 1
Veterans:
Pension: RS030223TA

Collected: 12/02/2025 7:46:00 AM
Copy to: DR JAMES ROGERS
Referred by: DR ROGER MOLESWORTH

Glucose

Glucose Fasting	4.5 mmol/L	3.6-6.0
-----------------	------------	---------

Glucose

NATA Accreditation No 2178

Glucose

Tests Completed: LFT(s), C(s), UCreat(s), E(s), Glu(p), Lipids HDL(s), Ca(s), CK(s), FBC(e)

Glucose

Tests Pending : Ferr(s), Vit D(s), PTH(e)

Glucose

Sample Pending :

Clinical Notes : OSTEOPOROSISV. CAROTID ATHEROMA. NOAC
CRESTOR 40MG EZETROL 10MG LEQVIOO 284MG FE
INFUSION SEPTEMBER 2024 VIT D SUPPLEMENT PRE
PROLIA

GLUCOSE

Date	14/12/23	27/06/24	01/11/24	12/02/25		
Time F-Fast	0736 F	0801 F	1009 F	0746 F		
Lab ID	837322679	851649973	851901462	893560721	Units	Reference

F Gluc Plasma	4.4	5.0	4.5	mmol/L	(3.6-6.0)
F Gluc Serum			4.9	mmol/L	(3.6-6.0)

NATA Accreditation No 2178

Tests Completed: LFT(s), C(s), UCreat(s), E(s), Glu(p), Lipids HDL(s),
Ca(s), CK(s), FBC(e)
Tests Pending : Ferr(s), Vit D(s), PTH(e)
Sample Pending :

End of Report :

Demographic Details					
Practice:	Mr	ROSEE	Paul	03/09/1943	Male
Lab:	893560721-C-C141	ROSEE	PAUL	03/09/1943	Male
Provider: Douglass Hanly Moir Pathology					

Reference Details	Collection Details	
Medicare: 2151 88807 9	1	Collected: 12/02/2025 7:46:00 AM
Veterans:		Copy to: DR JAMES ROGERS
Pension: RS030223TA		Referred by: DR ROGER MOLESWORTH

Investigation Result: ROSEE, Paul

Page 1 of 2

Biochemistry

Sodium	140 mmol/L	135-145	
Potassium	4.2 mmol/L	3.5-5.5	
Chloride	107 mmol/L	95-110	
Bicarbonate	25 mmol/L	20-32	
Urea	6.4 mmol/L	4.0-10.0	
Creatinine	105 umol/L	60-120	
Total Bilirubin	15 umol/L	4-20	
Alk Phos	68 U/L	35-110	
ALT	18 U/L	5-40	
AST	30 U/L	10-40	
Gamma GT	15 U/L	5-50	
LDH	217 U/L	120-250	
Albumin	42 g/L	34-45	
Globulin	24 g/L	23-39	
Total Protein	66 g/L	60-81	
Cholesterol	2.7 mmol/L	<5.5	
Triglycerides	1.2 mmol/L	<2.0	
Calcium	2.21 mmol/L	2.15-2.55	
Corrected Calcium	2.23 mmol/L	2.15-2.55	
CK	122 U/L	40-200	
eGFR	56 mL/min/1.73m2	>59	L
Status	Fasting		

Routine Biochemistry
Comment: Routine Biochemistry
eGFR (mL/min/1.73m2) calculated by CKD-EPI formula - see www.kidney.org.au

Routine Biochemistry
NATA Accreditation No 2178

Routine Biochemistry
Tests Completed: LFT(s), C(s), UCreat(s), E(s), Lipids HDL(s), Ca(s), CK(s), FBC(e)

Routine Biochemistry
Tests Pending : Glu(p), Ferr(s), Vit D(s), PTH(e)

Routine Biochemistry
Sample Pending :

Clinical Notes : OSTEOPOROSISV. CAROTID ATHEROMA. NOAC
 CRESTOR 40MG EZETROL 10MG LEQVIOO 284MG FE
 INFUSION SEPTEMBER 2024 VIT D SUPPLEMENT PRE
 PROLIA

BIOCHEMISTRY

Date	14/12/23	27/06/24	01/11/24	12/02/25		
Time F-Fast	0736 F	0801 F	1009 F	0746 F		
Lab ID	837322679	851649973	851901462	893560721	Units	Reference
Status	Fasting	Fasting	Fasting	Fasting		
Sodium	140	141	140	140	mmol/L	(135-145)
Potassium	4.3	4.9	4.7	4.2	mmol/L	(3.5-5.5)
Chloride	106	107	107	107	mmol/L	(95-110)
Bicarbonate	24	26	23	25	mmol/L	(20-32)
Urea	7.4	7.9	6.2	6.4	mmol/L	(4.0-10.0)
Creatinine	120	105	105	105	umol/L	(60-120)
eGFR	L 50	L 58	L 56	L 56	mL/min/1.73m2	(>59)
Calcium	2.48			2.21	mmol/L	(2.15-2.55)
Corr Calcium	2.40			2.23	mmol/L	(2.15-2.55)
Bili.Total	15	10	12	15	umol/L	(4-20)
ALP	73	65	75	68	U/L	(35-110)
GGT	12	12	13	15	U/L	(5-50)
LD	241	193	215	217	U/L	(120-250)
AST	28	24	28	30	U/L	(10-40)
ALT	20	15	23	18	U/L	(5-40)
Total Protein	72	68	72	66	g/L	(60-81)
Albumin	H 47	43	H 46	42	g/L	(34-45)
Globulin	25	25	26	24	g/L	(23-39)
Cholesterol	4.7	4.6	2.9	2.7	mmol/L	(<5.5)
Triglycerides	1.6	H 2.1	1.5	1.2	mmol/L	(<2.0)
CK	H 208	95	141	122	U/L	(40-200)

Comments on Collection 12/02/25 0746 F:
 eGFR (mL/min/1.73m2) calculated by CKD-EPI formula - see www.kidney.org.au

NATA Accreditation No 2178

Tests Completed: LFT(s), C(s), UCreat(s), E(s), Lipids HDL(s), Ca(s), CK(s), FBC(e)
 Tests Pending : Glu(p), Ferr(s), Vit D(s), PTH(e)
 Sample Pending :

End of Report :

Demographic Details			
Practice:	Mr	ROSEE	Paul
Lab:	893560721-H-H902	ROSEE	PAUL
Provider:	Douglass Hanly Moir Pathology		
03/09/1943 Male		03/09/1943 Male	

Reference Details	Collection Details
Medicare: 2151 88807 9 1	Collected: 12/02/2025 7:46:00 AM
Veterans:	Copy to: DR JAMES ROGERS
Pension: RS030223TA	Referred by: DR ROGER MOLESWORTH

Investigation Result: ROSEE, Paul

Page 1 of 2

Haematology

Haemoglobin	144 g/L	128-175
Red cell count	5.0 x10 ¹² /L	4.2-6.2
Haematocrit	0.44	0.36-0.53
MCH	28.6 pg	27.0-32.0
MCHC	329 g/L	310-360
MCV	87 fL	80-100
White cell count	8.3 x10 ⁹ /L	4.0-11.0
Platelets	255 x10 ⁹ /L	150-450
Neutrophils	5.25 x10 ⁹ /L	2.0-7.5
Lymphocytes	1.59 x10 ⁹ /L	1.0-4.0
Monocytes	0.96 x10 ⁹ /L	0.0-1.0
Basophils	0.06 x10 ⁹ /L	0.0-0.3
Eosinophils	0.47 x10 ⁹ /L	0.0-0.5
RDW	14.2	10.0-15.0
NRBC	<1.0 /100 WBC	<1

HAEMATOLOGY
Comment: HAEMATOLOGY
Full blood count is within reference limits

HAEMATOLOGY
NATA Accreditation No 2178

HAEMATOLOGY
Tests Completed: FBC(e)

HAEMATOLOGY
Tests Pending : LFT(s), C(s), UCreat(s), E(s), Glu(p), Lipids HDL(s), Ca(s), Ferr(s), CK(s), Vit D (s), PTH(e)

HAEMATOLOGY
Sample Pending :

Clinical Notes : OSTEOPOROSISV. CAROTID ATHEROMA. NOAC
CRESTOR 40MG EZETROL 10MG LEQVIOO 284MG FE
INFUSION SEPTEMBER 2024 VIT D SUPPLEMENT PRE
PROLIA

HAEMATOLOGY

Date 27/06/24 01/09/24 01/11/24 12/02/25

Demographic Details					
Practice:	Mr	ROSEE	Paul	03/09/1943	Male
Lab:	893560721-C-E355	ROSEE	PAUL	03/09/1943	Male
Provider: Douglass Hanly Moir Pathology					

Reference Details		Collection Details
Medicare:	2151 88807 9 1	Collected: 12/02/2025 7:46:00 AM
Veterans:		Copy to: DR JAMES ROGERS
Pension:	RS030223TA	Referred by: DR ROGER MOLESWORTH

Investigation Result: ROSEE, Paul

Page 1 of 2

PTH(e)

Albumin	42 g/L	34-45	
Calcium	2.21 mmol/L	2.15-2.55	
Corrected Calcium	2.23 mmol/L	2.15-2.55	
Intact Parathyroid Hormone	8.0 pmol/L	1.6-6.9	H

PARATHYROID HORMONE

History of denosumab (Prolia) therapy noted which also may be associated with elevated PTH.

PARATHYROID HORMONE

NATA Accreditation No 2178

PARATHYROID HORMONE

Tests Completed: LFT(s), C(s), UCreat(s), E(s), Glu(p), Lipids HDL(s), Ca(s), Ferr(s), CK(s), Vit D (s), PTH(e), FBC(e)

PARATHYROID HORMONE

Tests Pending :

PARATHYROID HORMONE

Sample Pending :

Clinical Notes : OSTEOPOROSISV. CAROTID ATHEROMA. NOAC
CRESTOR 40MG EZETROL 10MG LEQVIOO 284MG FE
INFUSION SEPTEMBER 2024 VIT D SUPPLEMENT PRE
PROLIA

Date	14/12/23	12/02/25		
Time F-Fast	0736 F	0746 F		
Lab ID	837322679	893560721	Units	Reference
PTH (Roche)	H 8.3	H 8.0	pmol/L	(1.6-6.9)
Calcium	2.48	2.21	mmol/L	(2.15-2.55)
Corr Calcium	2.40	2.23	mmol/L	(2.15-2.55)
Albumin	H 47	42	g/L	(34-45)

Comments on Collection 12/02/25 0746 F:
History of denosumab (Prolia) therapy noted which also may be associated with elevated PTH.

Investigation Result: ROSEE, Paul

Page 2 of 2

NATA Accreditation No 2178

Tests Completed: LFT(s), C(s), UCreat(s), E(s), Glu(p), Lipids HDL(s),
Ca(s), Ferr(s), CK(s), Vit D(s), PTH(e), FBC(e)

Tests Pending :

Sample Pending :

End of Report :

Time F-Fast Lab ID	0801 F 851649973	0849 837232274	1009 F 851901462	0746 F 893560721	Units	Reference
Haemoglobin	L 122	L 125	147	144	g/L	(128-175)
RCC	4.6	4.7	5.2	5.0	x10 ¹² /L	(4.2-6.2)
Haematocrit	0.37	0.39	0.46	0.44		(0.36-0.53)
MCV	L 79	82	88	87	fL	(80-100)
MCH	L 26.4	L 26.4	28.3	28.6	pg	(27.0-32.0)
MCHC	333	322	323	329	g/L	(310-360)
RDW	14.6	H 16.8	H 16.3	14.2		(10.0-15.0)
WCC	7.9	8.9	8.1	8.3	x10 ⁹ /L	(4.0-11.0)
Neutrophils	5.05	6.14	5.39	5.25	x10 ⁹ /L	(2.0-7.5)
Lymphocytes	1.82	1.54	1.57	1.59	x10 ⁹ /L	(1.0-4.0)
Monocytes	0.83	0.94	0.82	0.96	x10 ⁹ /L	(0.0-1.0)
Eosinophils	0.19	0.20	0.27	0.47	x10 ⁹ /L	(0.0-0.5)
Basophils	0.03	0.05	0.05	0.06	x10 ⁹ /L	(0.0-0.3)
NRBC	<1.0	<1.0	<1.0	<1.0	/100 WBC	(<1)
Platelets	265	302	273	255	x10 ⁹ /L	(150-450)
ESR	9				mm/h	(1-30)

Comments on Collection 12/02/25 0746 F:
Full blood count is within reference limits

NATA Accreditation No 2178

Tests Completed: FBC(e)
Tests Pending : LFT(s), C(s), UCreat(s), E(s), Glu(p), Lipids HDL(s),
Ca(s), Ferr(s), CK(s), Vit D(s), PTH(e)
Sample Pending :

End of Report :

Demographic Details					
Practice:	Mr	ROSEE	Paul	03/09/1943	Male
Lab:	893560721-C-C151	ROSEE	PAUL	03/09/1943	Male
Provider: Douglass Hanly Moir Pathology					

Reference Details	Collection Details	
Medicare: 2151 88807 9	1	Collected: 12/02/2025 7:46:00 AM
Veterans:		Copy to: DR JAMES ROGERS
Pension: RS030223TA		Referred by: DR ROGER MOLESWORTH

Investigation Result: ROSEE, Paul

Iron Studies

Ferritin 54 ug/L 30-300

Iron Studies
Comment: Iron Studies
History of iron therapy noted.

Iron Studies
NATA Accreditation No 2178

Iron Studies
Tests Completed: LFT(s), C(s), UCreat(s), E(s), Glu(p), Lipids HDL(s), Ca(s), Ferr(s), CK(s), Vit D (s), FBC(e)

Iron Studies
Tests Pending : PTH(e)

Iron Studies
Sample Pending :

Clinical Notes : OSTEOPOROSISV. CAROTID ATHEROMA. NOAC
CRESTOR 40MG EZETROL 10MG LEQVIOO 284MG FE
INFUSION SEPTEMBER 2024 VIT D SUPPLEMENT PRE
PROLIA

IRON

Date	27/06/24	01/08/24	01/11/24	12/02/25		
Time F-Fast	0801 F	0849	1009 F	0746 F		
Lab ID	851649973	837232274	851901462	893560721	Units	Reference
Iron	10.4	10.0			umol/L	(5.0-30.0)
Transferrin	3.1	H 3.4			g/L	(2.0-3.2)
TIBC (Calc)	68	H 74			umol/L	(46-70)
Saturation	15	14			%	(10-45)
Ferritin	L 21	L 18	50	54	ug/L	(30-300)

Comments on Collection 12/02/25 0746 F:
History of iron therapy noted.

NATA Accreditation No 2178

Tests Completed: LFT(s), C(s), UCreat(s), E(s), Glu(p), Lipids HDL(s)

Investigation Result: ROSEE, Paul

Page 2 of 2

Ca(s), Ferr(s), CK(s), Vit D(s), FBC(e)
Tests Pending : PTH(e)
Sample Pending :

End of Report :

Demographic Details			
Practice:	Mr	ROSEE	Paul
Lab:	893560721-C-C205	ROSEE	PAUL
Provider:	Douglass Hanly Moir Pathology		
			03/09/1943 Male
			03/09/1943 Male
Reference Details		Collection Details	
Medicare:	2151 88807 9	1	Collected: 12/02/2025 7:46:00 AM
Veterans:			Copy to: DR JAMES ROGERS
Pension:	RS030223TA		Referred by: DR ROGER MOLESWORTH

Investigation Result: ROSEE, Paul

Page 1 of 2

Lipids HDL(s)

Cholesterol	2.7 mmol/L	<5.5
HDL Cholesterol	1.2 mmol/L	>1.0
LDL Cholesterol	0.9 mmol/L	<3.0
Triglycerides	1.2 mmol/L	<2.0
Status	Fasting	
Non-HDL Cholesterol	1.5 mmol/L	<4.0

LIPIDS & HDL
Please note that the above reference limits are decision limits.
A flag based on these limits is an indication to review the absolute cardiovascular risk for the patient. For assessment of absolute cardiovascular disease risk please see www.cvdcheck.org.au

The above decision limits are based on the European Atherosclerosis Society (EAS) and European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Consensus Statement 2016 and the Australasian Association of Clinical Biochemistry and Laboratory Medicine (AACB) Lipid Reporting Guideline 2018.

Lipid treatment targets for patients at high risk of cardiovascular disease:

Total cholesterol	<4.0 mmol/L
Triglyceride	<2.0 mmol/L
HDL cholesterol	>1.0 mmol/L
LDL cholesterol	<2.5 mmol/L (<1.8 mmol/L for very high risk)
Non-HDL cholesterol	<3.3 mmol/L (<2.5 mmol/L for very high risk)

High risk - Primary prevention Very high risk - Secondary prevention

Target values from the AACB Lipid Reporting Guideline 2018.

Please note that as there is a continuum of risk, benefits are obtained for any measured lipid components moving towards and beyond the various target levels.

LIPIDS & HDL
NATA Accreditation No 2178

LIPIDS & HDL
Tests Completed: LFT(s),C(s),UCreat(s),E(s),Lipids HDL(s),Ca(s),CK(s),FBC(e)

LIPIDS & HDL
Tests Pending : Glu(p),Ferr(s),Vit D(s), PTH(e)

LIPIDS & HDL
Sample Pending :

Clinical Notes : OSTEOPOROSISV. CAROTID ATHEROMA. NOAC
 CRESTOR 40MG EZETROL 10MG LEQVIOO 284MG FE
 INFUSION SEPTEMBER 2024 VIT D SUPPLEMENT PRE
 PROLIA

Date	14/12/23	27/06/24	01/11/24	12/02/25		
Time F-Fast	0736 F	0801 F	1009 F	0746 F		
Lab ID	8373r2679	851649973	851901462	893560721	Units	Reference

Status	Fasting	Fasting	Fasting	Fasting		
Cholesterol	4.7	4.6	2.9	2.7	mmol/L	(<5.5)
Triglycerides	1.6	H 2.1	1.5	1.2	mmol/L	(<2.0)
HDL Chol.	1.3	1.1	1.3	1.2	mmol/L	(>1.0)
LDL Chol.	2.7	2.5	0.9	0.9	mmol/L	(<3.0)
Non-HDL Chol.	3.4	3.5	1.6	1.5	mmol/L	(<4.0)

Comments on Collection 12/02/25 0746 F:
 Please note that the above reference limits are decision limits.
 A flag based on these limits is an indication to review the absolute
 cardiovascular risk for the patient. For assessment of absolute
 cardiovascular disease risk please see www.cvdcheck.org.au

The above decision limits are based on the European Atherosclerosis Society
 (EAS) and European Federation of Clinical Chemistry and Laboratory Medicine
 (EFLM) Consensus Statement 2016 and the Australasian Association of
 Clinical Biochemistry and Laboratory Medicine (AACB) Lipid Reporting
 Guideline 2018.

Lipid treatment targets for patients at high risk of cardiovascular
 disease:

Total cholesterol	<4.0 mmol/L
Triglyceride	<2.0 mmol/L
HDL cholesterol	>1.0 mmol/L
LDL cholesterol	<2.5 mmol/L (<1.8 mmol/L for very high risk)
Non-HDL cholesterol	<3.3 mmol/L (<2.5 mmol/L for very high risk)

High risk - Primary prevention Very high risk - Secondary prevention

Target values from the AACB Lipid Reporting Guideline 2018.

Please note that as there is a continuum of risk, benefits are obtained for
 any measured lipid components moving towards and beyond the various target
 levels.

NATA Accreditation No 2178

Tests Completed: LFT(s), C(s), UCreat(s), E(s), Lipids HDL(s), Ca(s), CK(s), FBC(e)
 Tests Pending : Glu(p), Ferr(s), Vit D(s), PTH(e)
 Sample Pending :

End of Report :